Novartis to Invest 140 Billion Won in Korea's RLT Supply Chain...Building Production and Treatment Infrastructure
MOU Signed with Ministry of Health and Welfare
Expansion of Domestic Treatment Centers from 10 to 30
Improved Patient Access to Radioligand Therapies Anticipated
Novartis plans to invest approximately KRW 140 billion to build a domestic supply chain for radioligand therapy (RLT) in South Korea. By partnering with the government, the company aims to establish local manufacturing facilities, a logistics network, and a system to foster specialized talent, with the goal of increasing cancer patients' access to treatment and strengthening the competitiveness of the domestic radiopharmaceutical industry.
Jung Eunkyung, Minister of Health and Welfare, and Judith Love, Head of Novartis Asia-Pacific, Middle East, and Africa (APMA), are posing for a commemorative photo after signing a Memorandum of Understanding (MOU) to establish an ecosystem for the research, development, production, and treatment of radioligand therapy drugs in South Korea at the Novotel Ambassador Hotel in Yongsan, Seoul, on the 21st. Ministry of Health and Welfare
View original imageThe Ministry of Health and Welfare and Novartis announced on July 21 that they have signed a Memorandum of Understanding (MOU) at the Novotel Ambassador Hotel in Yongsan, Seoul, to create an ecosystem for research, development, production, and treatment of radioligand therapy drugs in South Korea.
RLT is a next-generation cancer treatment technology in which radioactive ligands bind to target proteins in cancer cells, break their DNA, and selectively destroy the cancer cells.
Under this agreement, Novartis will invest approximately KRW 140 billion to establish RLT manufacturing facilities within South Korea and to build an advanced cold chain logistics network. The company plans to expand RLT treatments, which are currently available at 10 medical institutions nationwide, to 30 hospitals. In addition, Novartis will develop new RLT drugs, nurture research and development professionals, and continue to work closely with the government to further improve patient access to RLT treatment.
Novartis has already invested in and collaborated with domestic pharmaceutical companies in various areas, including technology transfer and clinical research. The Ministry of Health and Welfare expects that this RLT production facility investment, which expands the achievements of previous collaborations into the advanced biotech sector, will enhance the research, development, and manufacturing capabilities for domestic radiopharmaceuticals, while also contributing to the growth of the advanced bioindustry ecosystem.
Jung Eunkyung, Minister of Health and Welfare, stated, "We sincerely welcome Novartis's decision to make a large-scale production investment in Korea, recognizing the country's outstanding technology and potential as a global leader in the pharmaceutical and biotech market." She added, "We hope that this agreement will provide innovative treatment options for patients in South Korea."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Judith Love, Head of Novartis Asia-Pacific, Middle East, and Africa (APMA), commented, "This agreement marks an important step in advancing the RLT ecosystem in Korea and strengthening the country's role in the future of medical innovation. We will work closely with the government and various healthcare stakeholders to ensure that more patients can benefit from innovative cancer treatments."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.